Thomas Sobik, PhD leads global business development for dsm‑firmenich’s Pharma business, partnering with clinicians, formulators and manufacturers to progress patient‑centric oral medicines. His current focus spans cannabinoid‑based therapeutics, solid CBD technologies (CBtru®) and pharma‑specific taste portfolio containing flavor tonalities, bitter maskers and receptor‑targeted bitter blockers, plus sensates taste solutions that improve adherence. Previously, he held commercial roles at W.R. Grace and Merck. Thomas earned a PhD in Neurobiology from Ruhr‑University Bochum and completed postdoctoral research before moving into industry.